Objectives This study aimed to determine the diagnostic and prognostic value of urinary biomarkers of intrinsic acute kidney injury (AKI) when patients were triaged in the emergency department. Background Intrinsic AKI is associated with nephron injury and results in poor clinical outcomes. Several urinary biomarkers have been proposed to detect and measure intrinsic AKI. Methods In a multicenter prospective cohort study, 5 urinary biomarkers (urinary neutrophil gelatinase–associated lipocalin, kidney injury molecule-1, urinary liver-type fatty acid binding protein, urinary interleukin-18, and cystatin C) were measured in 1,635 unselected emergency department patients at the time of hospital admission. We determined whether the biomarkers diagnosed intrinsic AKI and predicted adverse outcomes during hospitalization. Results All biomarkers were elevated in intrinsic AKI, but urinary neutrophil gelatinase-associated lipocalin was most useful (81% specificity, 68% sensitivity at a 104-ng/ml cutoff) and predictive of the severity and duration of AKI. Intrinsic AKI was strongly associated with adverse in-hospital outcomes. Urinary neutrophil gelatinase-associated lipocalin and urinary kidney injury molecule 1 predicted a composite outcome of dialysis initiation or death during hospitalization, and both improved the net risk classification compared with conventional assessments. These biomarkers also identified a substantial subpopulation with low serum creatinine at hospital admission, but who were at risk of adverse events. Conclusion Urinary biomarkers of nephron damage enable prospective diagnostic and prognostic stratification in the emergency department.
The V-Loc suture is associated with a significantly shorter time for the RSR and UVA compared with the traditional suture and is not associated with a higher incidence of clinical urinary leak; however, a larger randomized study with long-term follow-up is necessary to confirm these results.
Comorbidities were associated with FSD and specific comorbidities associated with dysfunction in specific domains. Urogynecologists and urologists must assess for comorbidities, as women presenting with sexual dysfunction may provide an opportunity for early diagnosis of life-threatening conditions.
Objectives The aim of this study was to report the prevalence of hydronephrosis associated with pelvic organ prolapse (POP). Methods We conducted a MEDLINE and PubMed search from 1996 to October 2016 using PRISMA guidelines. Eight studies met criteria for inclusion, including 3 prospective and 5 retrospective studies. Results The prevalence of hydronephrosis ranged from 3.5% to 30.6% in studies that included multiple stages of prolapse. Hydronephrosis correlated with prolapse severity in multiple studies, but serum creatinine did not consistently predict hydronephrosis. Two studies reported a significantly higher prevalence of hydronephrosis in patients with uterovaginal prolapse compared with vaginal vault prolapse. Complete resolution of hydronephrosis was described in 56% to 83% of patients after undergoing surgical treatment for advanced prolapse. Conclusions Hydronephrosis among patients with POP is not rare, and we suggest consideration of upper tract evaluation in patients presenting with POP, particularly in those with advanced uterovaginal prolapse electing to proceed with expectant or conservative management.
Background Many of the same mechanisms involved in the sexual arousal-response system in men exist in women and can be affected by underlying general medical conditions. Aim To assess whether sexual function in men and women is correlated with similar comorbidities. Methods This study was a secondary analysis of the 3rd National Survey of Sexual Attitudes and Lifestyles (Natsal-3), a prospective stratified probability sample of British individuals 16 to 74 years old interviewed from 2010 to 2012. We assessed for an association between sexual function and the following comorbidities: heart attack, heart disease, hypertension, stroke, diabetes, chronic lung disease, depression, other mental health conditions, other neurologic conditions, obesity, menopause, incontinence, smoking status, and age. Outcome An association was found between multiple medical comorbidities and sexual dysfunction in women and in men. Results 6,711 women and 4,872 men responded to the survey, were in a relationship, and reported sexual activity in the past year. The average age of the women was 35.4 ± 14.1 and that of the men was 36.8 ± 15.6. There was an association between sexual function and all variables assessed except for chronic lung disease, heart attack, and incontinence in women compared with stroke, other neurologic conditions, incontinence, and smoking status in men. Comorbidities associated with erectile dysfunction included depression, diabetes, and other heart disease, whereas comorbidities associated with difficulty with lubrication included depression and other heart disease. Menopause was predictive of sexual dysfunction. Male sexual function appeared to decline after 45.5 years of age. Clinical Implications Physicians should be aware of the correlation between medical comorbidities and sexual dysfunction in women and men and should ask patients about specific symptoms that might be associated with underlying medical conditions. Strengths and Limitations Use of a stratified probability sample compared with a convenience sample results in capturing of associations representative of the population. Inclusion of multiple comorbidities in the multivariate analysis allows us to understand the effects of several variables on sexual function. Although this study shows only an association, further research could determine whether there is a causal relation between comorbidities and sexual dysfunction in women. Conclusion Multiple medical comorbidities are associated with sexual dysfunction not only in men but also in women.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.